On the stock market since 2021, it operates in the world of health and science. It has 55 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $336.2M in the vault; even if every debt were paid off, $335.4M would remain.
Over the last 12 months, company executives reported 17 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $46.71 — 119% above today’s price.
A loss of $127.4M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 31/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 42/100.
On our five-subject report card, JBIO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: JBIO is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (45/100) says the stock isn’t cheap.